Myasthenia Gravis Treatment Market: Information by Type (Ocular MG, Congenital MG, Transient Neonatal MG), Treatment (Autologous HSCT, Surgery), End-User, Regional Outlook—Forecast Till 2026

May 14, 2019   Global Statistics Representing Myasthenia Gravis Treatment Market Scenario According to the Myasthenia Gravis Foundation of America, myasthenia gravis is one of the most common primary disorders of neuromuscular transmission. Around 14 to 20 out of every 100,000 people in the United States suffer from myasthenia gravis. While myasthenia gravis can affect people of all ages, it is more common in women under 40 and men older than 60. According to Elsevier, 1,283 New Zealanders are affected by a n...
Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1        Market Definition

1.2        Market Scope

2          Research Methodology

2.1        Primary Research

2.2        Research Methodology

2.3        Assumptions & Exclusions

2.4        Secondary Data Sources

3          Market Overview

3.1        Report Segmentation & Scope

3.2        Value Chain Analysis: Myasthenia Gravis Treatment Market

3.3        Key Market Trends

3.3.1     Drivers

3.3.2     Restraints

3.3.3     Opportunities

3.4        Porter’s Five Forces Analysis

3.4.1     Bargaining Power of Suppliers

3.4.2     Bargaining Power of Buyers

3.4.3     Threat of Substitution

3.4.4     Threat of New Entrants

3.4.5     Competitive Rivalry

3.5        Market Share Analysis

4          By Type Overview

4.1        Introduction

4.1.1     Market Size & Forecast (Value)

 4.2       Ocular MG

4.3        Congenital MG

4.4        Transient Neonatal MG

6          By Treatment

6.1        Introduction

6.1.1     Market Size & Forecast (Value)

6.2        Medication

6.3        Surgery

6.4        Autologous Hematopoietic Stem Cell Transplantation (HSCT)

6.5        Plasmapheresis & Intravenous Immunoglobulin

6.6        Others

7.         By End User

7.1        Introduction

7.1.1     Market Size & Forecast (Value)

7.2.       Hospitals

7.3        Clinics

7.4        Academic Research Institutes

7.5        Others

8.         Regional Overview                  

8.1        Introduction      

8.1.1     Market Size & Forecast (Value) 

8.2        America           

8.2.1     North America  

8.2.1.1  U.S.     

8.2.1.1.1           By Type           

8.2.1.1.2           By Treatment   

8.2.1.1.3           By End User                 

8.2.1.2  Canada

8.2.1.2.1           By Type          

8.2.1.2.2           By Treatment  

8.2.1.2.3           By End User                 

8.2.1.3  Mexico

8.2.1.3.1           By Type           

8.2.1.3.2           By Treatment   

8.2.1.3.3           By End User                 

8.2.2     Latin America   

8.2.2.1              By Type

8.2.2.2              By Treatment

8.2.2.3              By End User                 

8.3        Europe

8.3.1     Market Size & Forecast (Value) 

8.3.2     Germany          

8.3.2.1              By Type           

8.3.2.2             By Treatment   

8.3.2.3              By End User                 

8.3.3     France 

8.3.3.1              By Type           

8.3.3.2             By Treatment   

8.3.2.3              By End User                 

8.3. 4    U.K.     

8.3.4.1              By Type           

8.3.4.2              By Treatment   

8.3.4.3              By End User                 

8.3.5     Italy     

8.3.5.1              By Type           

8.3.5.2              By Treatment

8.3.5.3              By End User     

8.3.6     Spain   

8.3.6.1              By Type           

8.3.6.2              By Treatment    

8.3.6.3              By End User

8.3.7     Rest of Europe 

8.3.7.1              By Type

8.3.7.2              By Treatment

8.3.7.3              By End User

8.4        Asia Pacific     

8.4.1     Market Size & Forecast (Value) 

8.4.2     Japan  

8.4.2.1              By Type

8.4.2.2              By Treatment    

8.4.2.3              By End User

8.4.3     China   

8.4.3.1              By Type

8.4.3.2              By Treatment

8.4.3.3              By End User

8.4.4     Australia          

8.4.4.1              By Type           

8.4.4.2              By Treatment    

8.4.4.3              By End User

8.4.5     India    

8.4.5.1              By Type           

8.4.5.2              By Treatment    

8.4.5.3              By End User

8.4.6     South Korea     

8.4.6.1              By Type           

8.4.6.2              By Treatment

8.4.6.3              By End User     

8.4.6     Rest of Asia-Pacific      

8.4.6.1              By Type           

8.4.6.2              By Treatment    

8.4.6.3              By End User

8.5        Middle East & Africa     

8.5.1     Market Size & Forecast (Value) 

8.5.2     Saudi Arabia    

8.5.2.1              By Type           

8.5.2.2              By Treatment    

8.5.2.3              By End User

8.5.3     South Africa     

8.5.3.1              By Type           

8.5.5.2              By Treatment    

8.5.5.3              By End User

8.5.4     Kuwait 

8.5.4.1              By Type           

8.5.5.2              By Treatment

8.5.5.3              By End User     

8.5.5     Rest of Middle East & Africa     

8.5.5.1              By Type           

8.5.5.2              By Treatment

8.5.5.3              By End User

9.         Company Profile                     

9.1        Valeant Pharmaceuticals International    

9.1.1     Company Overview      

9.1.2     Financial Performance  

9.1.3     Recent Developments  

9.1.4     Product Portfolio          

9.2        Novartis Pharmaceuticals Corporation   

9.2.1     Company Overview      

9.2.2     Financial Performance  

9.2.3     Recent Developments  

9.2.4     Product Portfolio          

9.3        Apotex Corporation      

9.3.1     Company Overview      

9.3.2     Financial Performance  

9.3.3     Recent Developments  

9.3.4     Product Portfolio          

9.4        Teva Pharmaceutical Industries Ltd.      

9.4.1     Company Overview      

9.4.2     Financial Performance  

9.4.3     Recent Developments  

9.4.4     Product Portfolio          

9.5        RPG Life Sciences, Cipla          

9.5.1     Company Overview      

9.5.2     Financial Performance  

9.5.3     Recent Developments  

9.5.4     Product Portfolio          

9.6        F. Hoffmann Roche La Ltd.       

9.6.1     Company Overview      

9.6.2     Financial Performance  

9.6.3     Recent Developments  

9.6.4     Product Portfolio          

9.7        Bristol-Myers Squibb Company 

9.7.1     Company Overview      

9.7.2     Financial Performance  

9.7.3     Recent Developments  

9.7.4     Product Portfolio          

9.8        Biogen Inc.       

9.8.1     Company Overview      

9.8.2     Financial Performance  

9.8.3     Recent Developments  

9.8.4     Product Portfolio          

9.9        AbbVie Inc.      

9.9.1     Company Overview      

9.9.2     Financial Performance  

9.9.3     Recent Developments  

9.9.4     Product Portfolio          

9.10      GlaxoSmithKline plc     

9.10.1   Company Overview      

9.10.2   Financial Performance  

9.10.3   Recent Developments  

9.10.4   Product Portfolio          

9.11      Fresenius Kabi 

9.11.1   Company Overview      

9.11.2   Financial Performance  

9.11.3   Recent Developments  

9.11.4   Product Portfolio